

National Institute of Environmental Health Sciences Division of Translational Toxicology

# DASS App v2.0: Implementing OECD Guideline No. 497 Updates

Kimberly T. To<sup>1</sup>, Alexandre Borrel<sup>2\*</sup>, Emily Reinke<sup>2</sup>, Nicole Kleinstreuer<sup>3</sup>

<sup>1</sup>ICF, Reston, VA; <sup>2</sup>Inotiv, Research Triangle Park, NC; <sup>3</sup>NIH/NIEHS/DTT/NICEATM, Research Triangle Park, NC

# Background

- The National Toxicology Program's DASS App (https://ntp.niehs.nih.gov/go/40498) is an open-source web application for users to apply defined approaches (DA) for skin sensitization (DASS) to their own data.
- A DA consists of a defined set of information sources (e.g., in silico predictions, in chemico, or in vitro data) used in a fixed data interpretation procedure (e.g., a mathematical model or rule-based approach) to provide predictions without the need for expert judgment
- Figure 1 shows the adverse outcome pathway (AOP) for skin sensitization initiated by covalent binding to proteins (OECD 2014) and assays that address the first three key events (KEs) in the AOP. The Organisation for Economic Co-operation and Development (OECD) published Test Guideline No. 497 (TG 497; OECD) 2023) describing two DAs that use input data from these assays and in silico skin sensitization models.
- The DASS App implements two DAs from TG 497:
- The Integrated Testing Strategy (ITS) DA scores results from a KE1 assay, KE3 assay, and an in silico model to generate skin sensitization hazard (sensitizer vs. non-sensitizer) and potency predictions.

# **New Assay Options and Borderline Evaluation for the 203**

Users can now apply assay-specific decision trees to identify results within borderline range of the assay decision thresholds.

Assay Decision Trees with Borderline Evaluation	► Key Event 1
KE1 Assay: ADRA	
KE1 Assay: DPRA	Key Event 2
KE2 Assay: KeratinoSens	
KE2 Assay: LUSENS	Kau Event 0
KE3 Assay: GARDSkin	• Key Event 3

- The 2 out of 3 (2o3) DA predicts skin sensitization hazard using the majority outcome among a set of KE1, KE2, and KE3 assays.
- The ITS and 2o3 DAs were initially evaluated for TG 497 using a specific set of assays or in silico models. Additional assays and models that have a similar mechanistic basis and applicability domain are being evaluated for inclusion in TG 497.
- DASS App v2.0 introduces new features that align with pending updates to TG 497, ensuring the relevance of the web application as well as continued democratization of accepted new approach methodologies.

#### The latest update to the DASS App (v2.0) includes:

- Additional assay and model options for the ITS and 2o3 DAs.
- Evaluation of borderline results from assay run data for use in the 2o3 DA.
- Reference data from the Integrated Chemical Environment (ICE) for comparison with user's results.
- Interactive visualizations of user uploaded quantitative data to contextualize results.
- Newly designed graphical user interface.

# Figure 1. Skin Sensitization AOP and Assays Included in DASS App v2.0



KE-based OECD TG (442C, D, and E) include the assays listed in the boxes under KEs 1-3, respectively.

Abbreviations: ADRA = amino acid derivative reactivity assay; DPRA = direct peptide reactivity assay; GARDskin = genomic allergen rapid detection skin assay; h-CLAT = human cell-line activation test; IL-8 Luc = interleukin-8 reporter gene assay; U-SENS = U937 Cell Line Activation Test. <sup>†</sup>Assays included in the current DASS TG 497.

# **New Assay Options for the ITS**



#### 2o3 Results

Show 10 ∽ entries

Compound ID	DPRA	KeratinoSens 🔶	U-SENS	DA 2o3 Hazard 🔌
All	All	All	All	All
А	Positive	Positive	Positive	Positive
В	Borderline	Negative	Borderline	Borderline
С	Borderline	Borderline	Negative	Borderline
D	Negative	Negative	Positive	Negative
E	Inconclusive	Positive	Borderline	Inconclusive

KE3 Assay 😣		
KE3 Assay		
⊖ GARDskin ⊖ h-CLAT	○ IL-8 Luc	U-SENS
KE3 Worksheet		
U-SENS	•	
KE3 Data Columns 😣		
Chemical Identifier Column		
Compound	•	
Run Identifier Column		
Run	•	
Concentration Column		
Concentration	•	
U-SENS CD86 SI Column		
SI_CD86	•	
U-SENS Viability (%) Colum	n	
Viability	•	

#### The results of the borderline evaluation are used to generate 2o3 hazard predictions.

Downloadable results include individual and overall borderline evaluation outcomes, 2o3 hazard predictions, and a summary of user selections.

Previously limited to DPRA and h-CLAT, users can now apply the ITS using data from ADRA, GARDskin, and U-SENS.

		KE1 Assay					
		ADR	Α	DP	RA		
Sco	ore	Mean NAC & NAL Depletion (%)	NAC Depletion (%)	Mean Cys & Lys Depletion (%)	Cys Depletion (%)		
3	3	x ≥ 46.4	x ≥ 67.4	x ≥ 42.47	x ≥ 98.24		
2	2	15.5 ≤ x < 46.4	17.5 ≤ x < 67.4	22.62 ≤ x < 42.47	23.09 ≤ x < 98.24		
1	1	4.9 ≤ x < 15.5	5.6 ≤ x < 17.5	6.38 ≤ x < 22.62	13.89 ≤ x <23.09		
C	D	x < 4.9	x < 5.6	x < 6.38	x < 13.89		

<u>NAC</u> = N-acetyl cysteine; <u>NAL</u> = N-acetyl lysine

				1	T n
	GARDskin	h-CLAT	U-SENS		
Score	Input Conc (µM)	MIT (µg/mL)	EC150 (µg/mL)		
3	x ≤ 13.03	x ≤ 10	x ≤ 3		
2	13.03 < x ≤ 56.44	10 < x ≤ 150	3 < x ≤ 35		
1	x > 56.44	150 < x ≤ 5000	35 < x <200		
0	Negative	Negative	Negative		



Solaction

Flagged

Access the DASS App

https://ntp.niehs.nih.gov/go/952311

# **New Features for Evaluating Performance**





						Required Enupoint	Selection	riagge
2	NA	1	3	Positive	Inconclusive	DA	ITS	
1	NA	0	1	Inconclusive	Inconclusive	KE1 Assay	ADRA	
0	0	1	1	Negative	NC	KE3 Assay	GARDskin	
3	3	1	7	Positive	1A	KE1 Mean Depletion	ADRA_mean_dep	FALSE
0	NA	1	1	Inconclusive	Inconclusive	KE3 Quantiative Value	GARDskin_input_conc	FALSE
3	3	1	7	Positive	1A	In Silico Call	Derek_prediction	FALSE
1	2	1	4	Positive	1B	In Silico Applicability Domain	Derek_ad	FALSE
0	2	1	3	Positive	1B			
1	1	1	3	Positive	1B			
0	NA	1	1	Inconclusive	Inconclusive			

## References

OECD 2014. Guidance Document No. 168. https://doi.org/10.1787/9789264221444-en OECD 2023. Guideline No. 497: Defined Approaches on Skin Sensitisation. https://doi.org/10.1787/b92879a4-en.

### Acknowledgments

This project was funded with federal funds from NIEHS, NIH under Contract No. HHSN273201500010C. The views expressed above do not necessarily represent the official positions of any federal agency. Since the poster was written as part of the official duties of the authors, it can be freely copied.

\*Alexandre Borrel is currently affiliated with Sciome, Research Triangle Park, NC.

To get announcements of NICEATM activities, visit the NIH mailing list page for NICEATM News at https://list.nih.gov/cgi-bin/wa.exe?SUBED1=niceatm-I&A=1 and click "Subscribe."

#### National Institutes of Health • U.S. Department of Health and Human Services